Real-World Safety of Janus Kinase Inhibitors in Alopecia Areata: A Propensity Score-Matched Cohort Study of a Global Federated Health Network

Background/Objectives: Janus kinase inhibitors (JAKis) have transformed the treatment of alopecia areata (AA), but pivotal trials had short follow-ups and real-world long-term safety data remain scarce. We compared incident adverse outcomes between patients with AA exposed and not exposed to JAKis.